J. W. Chapman

2.0k total citations · 2 hit papers
15 papers, 1.4k citations indexed

About

J. W. Chapman is a scholar working on Oncology, Cancer Research and Genetics. According to data from OpenAlex, J. W. Chapman has authored 15 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 7 papers in Cancer Research and 6 papers in Genetics. Recurrent topics in J. W. Chapman's work include Estrogen and related hormone effects (6 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). J. W. Chapman is often cited by papers focused on Estrogen and related hormone effects (6 papers), Breast Cancer Treatment Studies (4 papers) and Advanced Breast Cancer Therapies (3 papers). J. W. Chapman collaborates with scholars based in United States, Canada and Switzerland. J. W. Chapman's co-authors include Kathleen I. Pritchard, Richard D. Gelber, Joseph P. Costantino, Clifford A. Hudis, Robert J. Gray, Joseph A. Sparano, Sally Hunsberger, Rebecca A. Enos, Jo Anne Zujewski and William E. Barlow and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

J. W. Chapman

15 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System

2007 558 citations Clifford A. Hudis, William E. Barlow et al. Journal of Clinical Oncology profile →
Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials

2008 534 citations Edward L. Korn, Sandra J. Lee et al. Journal of Clinical Oncology profile →

Peers

J. W. Chapman

ONCOL

IMMUN

PRM

Ignasi Tusquets Spain

Stephen Welch Canada

Karsten E. Weber Germany

Antonella Spila Italy

Cesar A. Santa‐Maria United States

Christos Vaklavas United States

Laura García‐Estévez Spain

Rosalin Cooper United Kingdom

Tracy Lively United States

Linnea Chap United States

Ignasi Tusquets Spain

J. W. Chapman

970 ×1.1

ONCOL

627 ×1.3

608 ×1.4

113 ×0.6

IMMUN

219 ×1.2

PRM

Citations per year, relative to J. W. Chapman J. W. Chapman (= 1×) peers Ignasi Tusquets

Countries citing papers authored by J. W. Chapman

Since Specialization

Citations

This map shows the geographic impact of J. W. Chapman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. W. Chapman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. W. Chapman more than expected).

Fields of papers citing papers by J. W. Chapman

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. W. Chapman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. W. Chapman. The network helps show where J. W. Chapman may publish in the future.

Co-authorship network of co-authors of J. W. Chapman

This figure shows the co-authorship network connecting the top 25 collaborators of J. W. Chapman. A scholar is included among the top collaborators of J. W. Chapman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. W. Chapman. J. W. Chapman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Wagner, Lynne I., Fengmin Zhao, Paul E. Goss, et al.. (2018). Patient-reported predictors of early treatment discontinuation: treatment-related symptoms and health-related quality of life among postmenopausal women with primary breast cancer randomized to anastrozole or exemestane on NCIC Clinical Trials Group (CCTG) MA.27 (E1Z03). Breast Cancer Research and Treatment. 169(3). 537–548. 60 indexed citations

Huang, Jessica, J. W. Chapman, Kim Leitzel, et al.. (2017). Impact of serum HER2, TIMP-1, and CAIX on outcome for HER2+ metastatic breast cancer patients: CCTG MA.31 (lapatinib vs. trastuzumab). Breast Cancer Research and Treatment. 164(3). 571–580. 11 indexed citations

Ingle, James N., Fang Xie, Matthew J. Ellis, et al.. (2016). Genetic Polymorphisms in the Long Noncoding RNA MIR2052HG Offer a Pharmacogenomic Basis for the Response of Breast Cancer Patients to Aromatase Inhibitor Therapy. Cancer Research. 76(23). 7012–7023. 43 indexed citations

Chapman, J. W., Lois E. Shepherd, James N. Ingle, et al.. (2016). Competing risks of death in women treated with adjuvant aromatase inhibitors for early breast cancer on NCIC CTG MA.27. Breast Cancer Research and Treatment. 156(2). 343–349. 10 indexed citations

Goss, Paul E., Dawn L. Hershman, Angela M. Cheung, et al.. (2014). Effects of adjuvant exemestane versus anastrozole on bone mineral density for women with early breast cancer (MA.27B): a companion analysis of a randomised controlled trial. The Lancet Oncology. 15(4). 474–482. 40 indexed citations

Aguilar‐Mahecha, Adriana, Mark Basik, J. W. Chapman, et al.. (2011). Measurement of baseline serum SDF-1 levels as a predictive biomarker for outcomes in the NCIC CTG MA.14 trial of octreotide, a somatostatin analogue in postmenopausal breast cancer.. Journal of Clinical Oncology. 29(15_suppl). 577–577. 1 indexed citations

Ingle, James N., Daniel J. Schaid, Taisei Mushiroda, et al.. (2009). A Genome-Wide Association Study in Patients Experiencing Musculoskeletal Adverse Events on Aromatase Inhibitors as Adjuvant Therapy in Early Breast Cancer Entered on NCIC CTG Trial MA.27. A Pharmacogenetics Research Network-RIKEN Collaboration.. Cancer Research. 69(24_Supplement). 15–15. 2 indexed citations

Stearns, Vered, J. W. Chapman, X. Cynthia, et al.. (2009). Treatment-Emergent Symptoms and the Risk of Breast Cancer Recurrence in the NCIC CTG MA.27 Adjuvant Aromatase Inhibitor Trial.. Cancer Research. 69(24_Supplement). 14–14. 7 indexed citations

Piura, Esther, J. W. Chapman, Allan Lipton, et al.. (2009). Serum 1-OH vitamin D (D) and prognosis of postmenopausal breast cancer (BC) patients: NCIC-CTG MA14 trial. Journal of Clinical Oncology. 27(15_suppl). 534–534. 15 indexed citations

10.

Pollak, Michaël, J. W. Chapman, Kathleen I. Pritchard, et al.. (2008). NCIC-CTG MA14 Trial: Tamoxifen (tam) vs. tam + octreotide (oct) for adjuvant treatment of stage I or II postmenopausal breast cancer. Journal of Clinical Oncology. 26(15_suppl). 532–532. 12 indexed citations

11.

Korn, Edward L., Sandra J. Lee, J. W. Chapman, et al.. (2008). Meta-Analysis of Phase II Cooperative Group Trials in Metastatic Stage IV Melanoma to Determine Progression-Free and Overall Survival Benchmarks for Future Phase II Trials. Journal of Clinical Oncology. 26(4). 527–534. 534 indexed citations breakdown →

12.

Hudis, Clifford A., William E. Barlow, Joseph P. Costantino, et al.. (2007). Proposal for Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials: The STEEP System. Journal of Clinical Oncology. 25(15). 2127–2132. 558 indexed citations breakdown →

13.

Chapman, J. W., L. E. Shepherd, J. N. Ingle, et al.. (2007). Competing causes of death in NCIC CTG MA.17, a placebo-controlled trial of letrozole as extended adjuvant therapy for breast cancer patients. Journal of Clinical Oncology. 25(18_suppl). 540–540. 1 indexed citations

14.

Pollak, Michaël, J. W. Chapman, Lois E. Shepherd, et al.. (2006). Insulin resistance, estimated by serum C-peptide level, is associated with reduced event-free survival for postmenopausal women in NCIC CTG MA.14 adjuvant breast cancer trial. Journal of Clinical Oncology. 24(18_suppl). 524–524. 34 indexed citations

15.

Rachmilewitz, Daniel, et al.. (1986). A multicenter international controlled comparison of two dosage regimens of misoprostol with cimetidine in treatment of gastric ulcer in outpatients. Digestive Diseases and Sciences. 31(S2). 75S–80S. 52 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact